We use cookies for a better user experience. Read our Privacy Policy

I Agree

Monoclonal Antibody Therapeutics Market Trends, 2016-2024

Monoclonal Antibody Therapeutics Market (Application - Cancer, Autoimmune Diseases, Infection, Hematological Diseases, Ophthalmological Diseases, and Others; Source - Human, Humanized, Chimeric, and Others; End User - Hospitals, Private Clinic and Research Institute) - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2016 - 2024

Global Monoclonal Antibody Therapeutics Market: Snapshot

The biological therapy used for treating various kinds of severe and chronic conditions are known as monoclonal antibodies. These are applied in the treatment of serious conditions such as cancer, rheumatoid arthritis, Crohn’s diseases, psoriasis, osteoporosis, systemic lupus erythematous and others. These are target only the affected areas to destroy the diseased cells, thus restoring the immune system. The research report by Transparency Market Research states that the global monoclonal antibody therapeutics market was worth US$86.7 bn in 2015 and is expected to reach US$245.8 bn by 2024. Between the forecast years of 2016 and 2024, the overall market is expected to rise at a CAGR of 12.6%.

The rising incidence of cancer across the globe is expected to drive the global market in the coming years. According to the World Health Organization, the world is expected to witness a rise of 70% in the number of cancer cases over the next few years. The statistics indicate that of these, 60% will be from Asia, Africa, and Latin America. The market is also likely to be favored by the growing approvals to research and develop new antibodies, especially across Europe and the U.S. Additionally, commercialization of these drugs will also contribute to the growing revenue of the global market.

monoclonal antibody therapeutics market

Autoimmune Diseases Showcase Steady Demand for Monoclonal Antibody Therapeutics

On the basis of application, the global monoclonal antibody therapeutics market is segmented into cancer, ophthalmological diseases, infection, autoimmune diseases, and hematological diseases among others. Of these, demand for treating autoimmune diseases with monoclonal antibody therapeutics is expected to remain at an all-time high in the coming years. The growing awareness about diseases, improving accessibility to healthcare, widening range of monoclonal antibody therapeutics, and huge investments in research and development of these therapeutics are expected to propel the segment in the coming years. Cancer is the second largest segment in the global market due to the high prevalence of the disease and an urgent need to treat the same.

North America to Remain Leading Segment due to Affordable Healthcare

In terms of geography, the global market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Analysts predict that the North America monoclonal antibody therapeutics market is likely to lead due to several reasons. Europe is expected to follow suit. As of 2015, the collective share of these two regions stood at 62.7% in the global market. The vast pool of geriatrics, well-established reimbursement policies, affordable healthcare, and growing awareness of diseases is expected to drive the market in North America in the coming few years. On the other hand, Europe monoclonal antibody therapeutics market is expected to thrive due to the increasing research and development in developing novel products.

Asia Pacific is also expected to show promise of a steady growth as the region has a huge population base with vast scope of unmet medical needs. The growing focus of governments in developing countries to improve the healthcare facilities is also expected to boost the demand for monoclonal antibody therapeutics in the coming years.

The key players operating in the global monoclonal antibody therapeutics market are GlaxoSmithKline Plc., Bayer AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., Sanofi, Merck & Co., Inc., AbbVie Inc., Novartis AG, Amgen Inc., Bristol – Myers Squibb Company, Johnson & Johnson, and Biogen Inc. among others.  The players are expected to focus on strategic mergers and acquisitions in the coming years to improve their foothold in the global market.

Monoclonal Antibody (mAb) Therapeutics Market Witnesses Massive Growth Potential in Demand for Drugs for Human Diseases

The pipeline of drugs in therapeutic antibodies has continuously grown in revenue potential. Over the past 25 years, therapeutic antibody drugs have opened new vistas in humanization of monoclonal antibodies (mAb), notably in the treatment of numerous cancer types, autoimmune disorders, and infectious diseases. A number of approvals of mAb by the U.S. FDA over the past three decades is a key trend from which has stemmed massive swatches of research investments by pharmaceutical companies in the monoclonal antibody (mAb) therapeutics market. Strides in the therapeutic antibody drugs pivot on advancements in purification technologies. A number of them are being investigated in clinical trials around the world, which is a key trend propelling the valuation growth in the monoclonal antibody (mAb) therapeutics market. One such technique is complementary-determining region (CDR) grafting, highly production in the development of humanized antibodies. Growing demand for biologics for autoimmune diseases and conditions that need prolonged treatment has been expanding the canvas for approval of therapeutic mAbs. The growing approval of human antibody drugs in recent years underscores the significant growth potential of the monoclonal antibody (mAb) therapeutics market.

Medical researchers are relentlessly pursuing the objectives of increasing the safety and efficacy of the existing therapeutic antibodies. Thus, pharmaceutical companies developing antibody-based drugs have made therapeutic breakthroughs. Continuing efforts complemented by technological advancements will likely pave way to improved classes of drugs in several diseases. These include asthma, Crohn’s disease, arthritis, transplant rejection, and migraine headaches. In particular, new platforms for developing bispecific antibodies are likely to bring new avenues in infectious diseases. In the current scenario of severe acute respiratory syndrome coronavirus 2, named as COVID-19, there is a pressing need for emergency authorization of monoclonal antibody (mAb) therapeutics. These hold promise in lowering the viral load and the severity of hospitalization. A large part of public resources are aimed at boosting the necessary medical infrastructure, and mAb, shows new paths of reducing the disease severity. 

The monoclonal antibody therapeutics market has been segmented as follows:

By Application

  • Cancer
  • Autoimmune diseases
  • Infection
  • Hematological diseases
  • Ophthalmological diseases
  • Others

By Source

  • Human
  • Humanized
  • Chimeric
  • Others

By End Users

  • Hospitals
  • Private Clinics
  • Research Institute

By Geography

  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Europe
    • U.K.
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • India
    • Japan
    • China
    • Australia
    • New Zealand
    • Rest of Asia Pacific
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • A.E.
    • Rest of MEA
Monoclonal Antibody Therapeutics Market Trends, 2016-2024

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of monoclonal antibody therapeutics market?

Monoclonal antibody therapeutics market is expected to reach US$245.8 bn by 2024

What is the anticipated CAGR of the monoclonal antibody therapeutics market in the forecast period?

Monoclonal antibody therapeutics market is expected to rise at a CAGR of 12.6% from 2016 to 2024

What are the key driving factors for the growth of the monoclonal antibody therapeutics market?

Monoclonal antibody therapeutics market is driven by rising incidence of cancer across the globe

Which region is expected to project the highest market share in the global monoclonal antibody therapeutics market?

North America’s monoclonal antibody therapeutics market is projected to hold a dominating share during the forecast period of 2016-2024

Who are the key players in the global monoclonal antibody therapeutics market?

The key players operating in the monoclonal antibody therapeutics market are Bayer AG, GlaxoSmithKline Plc., Sanofi, Novartis AG, Hoffmann-La Roche Ltd., AbbVie Inc., and Pfizer Inc.

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Monoclonal Antibody Therapeutics Market 

4. Market Overview
     4.1. Introduction
            4.1.1. Application Definition
            4.1.2. Industry Evolution / Developments
     4.2.  Overview
     4.3. Key Market Indicators
            4.3.1. Region/Country Specific
            4.3.2. Product/Application/End Users Specific
            4.3.3. Target Market Specific – Global Scenario
     4.4. Market Dynamics
            4.4.1. Drivers
            4.4.2. Restraints
            4.4.3. Opportunity
     4.5. Global Monoclonal Antibody Therapeutics Market  Analysis and Forecasts, 2014–2024
            4.5.1. Market Revenue Projections (US$ Mn)
     4.6. Monoclonal Antibody Therapeutics Market  - Global Supply Demand Scenario
     4.7. Porter’s Five Force Analysis
     4.8. Value Chain Analysis
     4.9. Market Outlook

5. Global Monoclonal Antibody Therapeutics Market  Analysis and Forecasts, By Application 
     5.1. Introduction & Definition
     5.2. Key Findings / Developments
     5.3. Key Trends
     5.4. Market Value  Forecast By Application , 2014–2024
            5.4.1. Cancer 
            5.4.2. Autoimmune diseases 
            5.4.3. Infection 
            5.4.4. Hematological diseases 
            5.4.5. Ophthalmological diseases 
            5.4.6. Others
     5.5. Market Attractiveness By Application 

6. Global Monoclonal Antibody Therapeutics Market  Analysis and Forecasts, By Source 
     6.1. Introduction & Definition
     6.2. Key Findings / Developments
     6.3. Key Trends
     6.4. Market Value  Forecast By Source , 2014–2024
            6.4.1. Human 
            6.4.2. Humanized 
            6.4.3. Chimeric 
            6.4.4. Others 
     6.5. Market Attractiveness By Source 

7. Global Monoclonal Antibody Therapeutics Market  Analysis and Forecasts, By End Users 
     7.1. Introduction & Definition
     7.2. Key Findings / Developments
     7.3. Key Trends
     7.4. Market Value  Forecast By End Users , 2014–2024
            7.4.1. Hospital
            7.4.2. Private Clinic 
            7.4.3. Research Institutes 
     7.5. Market Attractiveness By End Users 

8. Global Monoclonal Antibody Therapeutics Market  Analysis and Forecasts, By Region
     8.1. Key Findings
     8.2. Policies and Regulations
     8.3. Market Value  Forecast By Region
            8.3.1. North America 
            8.3.2. Europe 
            8.3.3. Asia Pacific 
            8.3.4. Latin America  
            8.3.5. Middle East & Africa 
     8.4. Market Attractiveness By Country/Region

9. North America Monoclonal Antibody Therapeutics Market  Analysis and Forecast
     9.1. Introduction
            9.1.1. Key Findings
            9.1.2. Key Trends
     9.2. Market Value  Forecast By Application , 2014–2024
            9.2.1. Cancer 
            9.2.2. Autoimmune diseases 
            9.2.3. Infection 
            9.2.4. Hematological diseases 
            9.2.5. Ophthalmological diseases 
            9.2.6. Others
     9.3. Market Value  Forecast By Source , 2014–2024
            9.3.1. Human 
            9.3.2. Humanized 
            9.3.3. Chimeric 
            9.3.4. Others 
     9.4. Market Value  Forecast By End Users , 2014–2024
            9.4.1. Hospital
            9.4.2. Private Clinic 
            9.4.3. Research Institutes 
     9.5. Market Value  Forecast By Country , 2014–2024
            9.5.1. U.S.
            9.5.2. Canada
     9.6. Market Attractiveness Analysis 
            9.6.1. By Application 
            9.6.2. By Source 
            9.6.3. By End Users 
            9.6.4. By Country

10. Europe Monoclonal Antibody Therapeutics Market  Analysis and Forecast
     10.1.Introduction
            10.1.1. Key Findings
            10.1.4. Key Trends
     10.2.Market Value  Forecast By Application , 2014–2024
            10.2.1. Cancer 
            10.2.2. Autoimmune diseases 
            10.2.3. Infection 
            10.2.4. Hematological diseases 
            10.2.5. Ophthalmological diseases 
            10.2.6. Others
     10.3.Market Value  Forecast By Source , 2014–2024
            10.3.1. Human 
            10.3.2. Humanized 
            10.3.3. Chimeric 
            10.3.4. Others 
     10.4.Market Value  Forecast By End Users , 2014–2024
            10.4.1. Hospital
            10.4.2. Private Clinic 
            10.4.3. Research Institutes 
     10.5.Market Value  Forecast By Country , 2014–2024
            10.5.1. Germany
            10.5.2. U.K.
            10.5.3. France
            10.5.4. Spain
            10.5.5. Italy
            10.5.6. Rest of Europe 
     10.6.Market Attractiveness Analysis 
            10.6.1. By Application 
            10.6.2. By Source 
            10.6.3. By End Users 
            10.6.4. By Country

11. Asia Pacific Monoclonal Antibody Therapeutics Market  Analysis and Forecast
     11.1.Introduction
            11.1.1. Key Findings
            11.1.4. Key Trends
     11.2.Market Value  Forecast By Application , 2014–2024
            11.2.1. Cancer 
            11.2.2. Autoimmune diseases 
            11.2.3. Infection 
            11.2.4. Hematological diseases 
            11.2.5. Ophthalmological diseases 
            11.2.6. Others
     11.3.Market Value  Forecast By Source , 2014–2024
            11.3.1. Human 
            11.3.2. Humanized 
            11.3.3. Chimeric 
            11.3.4. Others 
     11.4.Market Value  Forecast By End Users , 2014–2024
            11.4.1. Hospital
            11.4.2. Private Clinic 
            11.4.3. Research Institutes 
     11.5.Market Value  Forecast By Country , 2014–2024
            11.5.1. Japan
            11.5.2. China
            11.5.3. Australia
            11.5.4. New Zealand
            11.5.5. India
            11.5.6. Rest of Asia Pacific
     11.6.Market Attractiveness Analysis 
            11.6.1. By Application 
            11.6.2. By Source 
            11.6.3. By End Users 
            11.6.4. By Country

12. Latin America  Monoclonal Antibody Therapeutics Market  Analysis and Forecast
     12.1.Introduction
            12.1.1. Key Findings
            12.1.4. Key Trends
     12.2.Market Value  Forecast By Application , 2014–2024
            12.2.1. Cancer 
            12.2.2. Autoimmune diseases 
            12.2.3. Infection 
            12.2.4. Hematological diseases 
            12.2.5. Ophthalmological diseases 
            12.2.6. Others
     12.3.Market Value  Forecast By Source , 2014–2024
            12.3.1. Human 
            12.3.2. Humanized 
            12.3.3. Chimeric 
            12.3.4. Others 
     12.4.Market Value  Forecast By End Users , 2014–2024
            12.4.1. Hospital
            12.4.2. Private Clinic 
            12.4.3. Research Institutes 
     12.5.Market Value  Forecast By Country , 2014–2024
            12.5.1. Brazil
            12.5.2. Mexico
            12.5.3. Rest of Latin America 
     12.6.Market Attractiveness Analysis 
            12.6.1. By Application 
            12.6.2. By Source 
            12.6.3. By End Users 
            12.6.4. By Country

13. Middle East & Africa Monoclonal Antibody Therapeutics Market  Analysis and Forecast
     13.1.Introduction
            13.1.1. Key Findings
            13.1.4. Key Trends
     13.2.Market Value  Forecast By Application , 2014–2024
            13.2.1. Cancer 
            13.2.2. Autoimmune diseases 
            13.2.3. Infection 
            13.2.4. Hematological diseases 
            13.2.5. Ophthalmological diseases 
            13.2.6. Others
     13.3.Market Value  Forecast By Source , 2014–2024
            13.3.1. Human 
            13.3.2. Humanized 
            13.3.3. Chimeric 
            13.3.4. Others 
     13.4.Market Value  Forecast By End Users , 2014–2024
            13.4.1. Hospital
            13.4.2. Private Clinic 
            13.4.3. Research Institutes 
     13.5.Market Value  Forecast By Country , 2014–2024
            13.5.1. South Africa
            13.5.2. UAE
            13.5.3. Saudi Arabia
            13.5.4. Rest of Middle East and Africa 
     13.6.Market Attractiveness Analysis 
            13.6.1. By Application 
            13.6.2. By Source 
            13.6.3. By End Users 
            13.6.4. By Country

14. Competition Landscape
     14.1.Market Player – Competition Matrix (By Tier and Size of companies)
     14.2.Market Share Analysis By Company (2015)
     14.3.Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
            14.3.1. Bayer AG
                      14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                      14.3.1.2. Financial Overview
                      14.3.1.3. Product Portfolio
                      14.3.1.4. SWOT Analysis 
                      14.3.1.5. Strategic Overview
            14.3.2. F. Hoffmann-La Roche Ltd. 
                      14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                      14.3.2.2. Financial Overview
                      14.3.2.3. Product Portfolio
                      14.3.2.4. SWOT Analysis 
                      14.3.2.5. Strategic Overview
            14.3.3. Pfizer, Inc. 
                      14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                      14.3.3.2. Financial Overview
                      14.3.3.3. Product Portfolio
                      14.3.3.4. SWOT Analysis 
                      14.3.3.5. Strategic Overview
            14.3.4. Sanofi
                      14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                      14.3.4.2. Financial Overview
                      14.3.4.3. Product Portfolio
                      14.3.4.4. SWOT Analysis 
                      14.3.4.5. Strategic Overview
            14.3.5. GlaxoSmithKline plc.
                      14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                      14.3.5.2. Financial Overview
                      14.3.5.3. Product Portfolio
                      14.3.5.4. SWOT Analysis 
                      14.3.5.5. Strategic Overview 
            14.3.6. Merck & Co., Inc. 
                      14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                      14.3.6.2. Financial Overview
                      14.3.6.3. Product Portfolio
                      14.3.6.4. SWOT Analysis 
                      14.3.6.5. Strategic Overview
            14.3.7. Novartis AG 
                      14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                      14.3.7.2. Financial Overview
                      14.3.7.3. Product Portfolio
                      14.3.7.4. SWOT Analysis 
                      14.3.7.5. Strategic Overview
            14.3.8. AbbVie Inc. 
                      14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                      14.3.8.2. Financial Overview
                      14.3.8.3. Product Portfolio
                      14.3.8.4. SWOT Analysis 
                      14.3.8.5. Strategic Overview
            14.3.9. Amgen Inc. 
                      14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                      14.3.9.2. Financial Overview
                      14.3.9.3. Product Portfolio
                      14.3.9.4. SWOT Analysis 
                      14.3.9.5. Strategic Overview
            14.3.10. Johnson & Johnson
                      14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
                      14.3.10.2. Financial Overview
                      14.3.10.3. Product Portfolio
                      14.3.10.4. SWOT Analysis 
                      14.3.10.5. Strategic Overview 
            14.3.11. Bristol-Myers Squibb Company 
                      14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
                      14.3.11.2. Financial Overview
                      14.3.11.3. Product Portfolio
                      14.3.11.4. SWOT Analysis 
                      14.3.11.5. Strategic Overview
            14.3.12. Biogen Inc. 
                      14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
                      14.3.12.2. Financial Overview
                      14.3.12.3. Product Portfolio
                      14.3.12.4. SWOT Analysis 
                      14.3.12.5. Strategic Overview

List of Tables

Table 01: Global Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Application, 2014–2024
Table 02: Global Market Size (US$ Mn) Forecast, by Source, 2014–2024
Table 03: Global Market Size (US$ Mn) Forecast, by End Users, 2014–2024
Table 04: Global Market Size (US$ Mn) Forecast, by Region, 2014–2024
Table 05: North America Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Application, 2014–2024
Table 06: North America Market Size (US$ Mn) Forecast, by Source, 2014–2024
Table 07: North America Market Forecast, by End Users, 2014–2024
Table 08: North America Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 09: Europe Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Application, 2014–2024
Table 10: Europe Market Size (US$ Mn) Forecast, by Source, 2014–2024
Table 11: Europe Monoclonal Antibody Therapeutics Market Forecast, by End Users, 2014–2024
Table 12: Europe Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 13: Asia Pacific Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Application, 2014–2024
Table 14: Asia Pacific Market Size (US$ Mn) Forecast, by Source, 2014–2024
Table 15: Asia Pacific Monoclonal Antibody Therapeutics Market Forecast, by End Users, 2014–2024
Table 16: Asia Pacific Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 17: Latin America Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Application, 2014–2024
Table 18: Latin America Market Size (US$ Mn) Forecast, by Source, 2014–2024
Table 19: Latin America Market Forecast, by End Users, 2014–2024
Table 20: Latin America Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 21: MEA Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Application, 2014–2024
Table 22: MEA Market Size (US$ Mn) Forecast, by Source, 2014–2024
Table 23: MEA Market Forecast, by End Users, 2014–2024
Table 24: MEA Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Country, 2014–2024

List of Figures

Figure  1: Market Value Share By Application (2016) Revenue (US$ Mn)
Figure  2: Market Value Share By Source(2016) Revenue (US$ Mn)
Figure  3: Market Value Share By Application & Source (2016) Revenue (US$ Mn)
Figure  3: Market Value Share By End Users  (2016) Revenue (US$ Mn)
Figure  4: Market Value Share By Region (2016) Revenue (US$ Mn)
Figure  3: Market Value Share By End Users & Region (2016) Revenue (US$ Mn)
Figure  5: Global Monoclonal Antibody Therapeutics Market Value Share Analysis, by Application, 2015 and 2024
Figure  6: Global Cancer  Market Revenue (US$ Mn), 2014–2024
Figure  7: Global Autoimmune diseases Market Revenue (US$ Mn), 2014–2024
Figure  8: Global Infection Market Revenue (US$ Mn), 2014–2024
Figure  9: Global Hematological diseases  Market Revenue (US$ Mn), 2014–2024
Figure  10: Global Ophthalmic diseases Market Revenue (US$ Mn), 2014–2024
Figure  11: Global Others Market Revenue (US$ Mn), 2014–2024
Figure  12: Global Monoclonal Antibody Therapeutics Market Attractiveness Analysis By Application, 2015
Figure  13: Global Monoclonal Antibody Therapeutics Market Value Share Analysis, by Source, 2015 and 2024
Figure  14: Global Human Market Revenue (US$ Mn), 2014–2024
Figure  15: Global Humanized Market Revenue (US$ Mn), 2014–2024
Figure  16: Global Chimeric Market Revenue (US$ Mn), 2014–2024
Figure  17: Global Others Market Revenue (US$ Mn), 2014–2024
Figure  18: Global Monoclonal Antibody Therapeutics Market Attractiveness Analysis By Source, 2015
Figure  19: Global Monoclonal Antibody Therapeutics Market Value Share Analysis, by End Users, 2015 and 2024
Figure  20: Global Hospital Market Revenue (US$ Mn), 2014–2024
Figure  21: Global Private Clinics Market Revenue (US$ Mn), 2014–2024
Figure  22: Global Research Institutes  Market Revenue (US$ Mn), 2014–2024
Figure  23: Global Monoclonal Antibody Therapeutics Market Attractiveness Analysis By End Users, 2015
Figure  24: Global Monoclonal Antibody Therapeutics Market Value Share Analysis, by Region, 2015 and 2024
Figure  25: Global Monoclonal Antibody Therapeutics Market Attractiveness Analysis By Region, 2015
Figure  26: North America Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, 2015–2024
Figure  27: North America Monoclonal Antibody Y-o-Y Growth Projections, 2015–2024
Figure  28: North America Monoclonal Antibody Therapeutics  Market Attractiveness By Country, 2014–2024
Figure  29: North America Market Value Share Analysis, by Application, 2015 and 2024
Figure  30: North America Market Value Share Analysis, by Source, 2015 and 2024
Figure  31: North America Market Value Share Analysis, by End Users, 2015 and 2024
Figure  32: North America Market by Country, 2015 and 2024
Figure  33: North America Monoclonal Antibody Therapeutics Market Attractiveness Analysis, by Application, 2015
Figure  34: North America Market Attractiveness Analysis, by Source, 2015
Figure  35: North America Market Attractiveness Analysis, By End users, 2015
Figure  36 : Europe Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, 2015–2024
Figure  37: Europe Monoclonal Antibody Y-o-Y Growth Projections, 2015–2024
Figure  38: Europe  Market Attractiveness By Country, 2014–2024
Figure  39: Europe Market Value Share Analysis, by Application, 2015 and 2024
Figure  40 : Europe Monoclonal Antibody Therapeutics Market Value Share Analysis, by Source, 2015 and 2024
Figure  41: Europe Market Value Share Analysis, by End Users, 2015 and 2024
Figure  42: Europe Monoclonal Antibody Therapeutics Market by Country, 2015 and 2024
Figure  43: Europe Market Attractiveness Analysis, by Application, 2015
Figure  44: Europe Market Attractiveness Analysis, by Source, 2015
Figure  45: Europe Market Attractiveness Analysis, by End Users, 2015
Figure  46: Asia Pacific Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, 2015–2024
Figure  47: Asia Pacific Monoclonal Antibody Y-o-Y Growth Projections, 2015–2024
Figure  48: Asia Pacific Market Attractiveness By Country, 2014–2024
Figure  49: Asia Pacific Monoclonal Antibody Therapeutics Market Value Share Analysis, by Application, 2015 and 2024
Figure  50: Asia Pacific Market Value Share Analysis, by Source, 2015 and 2024
Figure  51: Asia Pacific Monoclonal Antibody Therapeutics Market Value Share Analysis, by End Users, 2015 and 2024
Figure  52: Asia Pacific Market by Country, 2015 and 2024
Figure  53: Asia Pacific Monoclonal Antibody Therapeutics Market Attractiveness Analysis, by Application, 2015
Figure  54: Asia Pacific Market Attractiveness Analysis, by Source, 2015
Figure  55: Asia Pacific Monoclonal Antibody Therapeutics Market Attractiveness Analysis, by End Users, 2015
Figure  56: Latin America Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, 2015–2024
Figure  57: Latin America Monoclonal Antibody Y-o-Y Growth Projections, 2015–2024
Figure  58: Latin America Monoclonal Antibody Therapeutics  Market Attractiveness By Country, 2014–2024
Figure  59: Latin America Market Value Share Analysis, by Application, 2015 and 2024
Figure  60: Latin America Monoclonal Antibody Therapeutics Market Value Share Analysis, by Source, 2015 and 2024
Figure  61: Latin America Market Value Share Analysis, by End Users, 2015 and 2024
Figure  62: Latin America Monoclonal Antibody Therapeutics Market by Country, 2015 and 2024
Figure  63: Latin America Market Attractiveness Analysis, by Application, 2015
Figure  64: Latin America Monoclonal Antibody Therapeutics Market Attractiveness Analysis, by Source, 2015
Figure  65: Latin America Market Attractiveness Analysis, by End Users, 2015
Figure  66: MEA Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, 2015–2024
Figure  67: MEA Monoclonal Antibody Y-o-Y Growth Projections, 2015–2024
Figure  68: MEA Monoclonal Antibody Therapeutics  Market Attractiveness By Country, 2014–2024
Figure  69: MEA Market Value Share Analysis, by Application, 2015 and 2024
Figure  70: MEA Monoclonal Antibody Therapeutics Market Value Share Analysis, by Source, 2015 and 2024
Figure  71: MEA Market Value Share Analysis, by End Users, 2015 and 2024
Figure  72: MEA Monoclonal Antibody Therapeutics Market by Country, 2015 and 2024
Figure  73: MEA Monoclonal Antibody Therapeutics Market Attractiveness Analysis, by Application, 2015
Figure  74: MEA Monoclonal Antibody Therapeutics Market Attractiveness Analysis, by Source, 2015
Figure  75: MEA Monoclonal Antibody Therapeutics Market Attractiveness Analysis, by End Users, 2015
Figure  76: Global Monoclonal Antibody Therapeutics Market Share Analysis, by Company (2015)

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

812

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved